BridgeBio Pharma (BBIO) Non-Current Assets (2018 - 2026)
BridgeBio Pharma (BBIO) posted Non-Current Assets of $129.7 million for Q1 2026, down 6.22% sequentially from $138.3 million in Q4 2025, and down 30.46% YoY from $186.5 million in Q1 2025.
BridgeBio Pharma (BBIO) Non-Current Assets (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Non-Current Assets for 9 years, with the latest figure at $129.7 million in Q1 2026.
- Quarterly Non-Current Assets fell 30.46% year-over-year to $129.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $594.7 million (down 24.11% YoY) and the FY2025 annual result came in at $138.3 million, down 30.39% from the prior year.
- Non-Current Assets fell to $129.7 million in Q1 2026 per BBIO's latest filing, from $138.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $220.4 million in Q3 2024 and troughed at $65.9 million in Q1 2024.
- A 5-year average of $121.9 million and a median of $96.9 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets sank 47.0% in 2022, then surged 227.3% in 2024.
- Over 5 years, Non-Current Assets stood at $74.2 million in 2022, then slipped by 7.27% to $68.8 million in 2023, then soared by 188.78% to $198.6 million in 2024, then slumped by 30.39% to $138.3 million in 2025, then dropped by 6.22% to $129.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $129.7 million, $138.3 million, and $158.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | 124.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124.16 Mn |
| Mar 31, 2026 | 129.68 Mn |
| Dec 31, 2025 | 138.28 Mn |
| Sep 30, 2025 | 158.87 Mn |
| Jun 30, 2025 | 167.91 Mn |
| Mar 31, 2025 | 186.47 Mn |
| Dec 31, 2024 | 198.65 Mn |
| Sep 30, 2024 | 220.40 Mn |
| Jun 30, 2024 | 178.14 Mn |
| Mar 31, 2024 | 65.91 Mn |
| Dec 31, 2023 | 68.79 Mn |
| Sep 30, 2023 | 67.34 Mn |
| Jun 30, 2023 | 70.78 Mn |
| Mar 31, 2023 | 72.98 Mn |
| Dec 31, 2022 | 74.18 Mn |
| Sep 30, 2022 | 86.52 Mn |
| Jun 30, 2022 | 90.95 Mn |
| Mar 31, 2022 | 96.92 Mn |
| Dec 31, 2021 | 123.93 Mn |
| Sep 30, 2021 | 141.81 Mn |